Cargando…
Polysubstance Use After Frontal Lobe Syndrome: A Case Report
INTRODUCTION: Frontal lobe syndrome (FLS) is a clinical condition characterized by personality and behavioral changes that usually occur after a traumatic brain injury (TBI). The main features of this syndrome are related to the deterioration of basic functions of the frontal lobe. Substance use dis...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567839/ http://dx.doi.org/10.1192/j.eurpsy.2022.2142 |
_version_ | 1784809499892121600 |
---|---|
author | Ulusoy, M. Ergelen, M. |
author_facet | Ulusoy, M. Ergelen, M. |
author_sort | Ulusoy, M. |
collection | PubMed |
description | INTRODUCTION: Frontal lobe syndrome (FLS) is a clinical condition characterized by personality and behavioral changes that usually occur after a traumatic brain injury (TBI). The main features of this syndrome are related to the deterioration of basic functions of the frontal lobe. Substance use disorder (SUD) is rare but also serious comorbiditiy seen after TBI. OBJECTIVES: In this case report, we aimed to discuss a case who developed SUD after TBI. METHODS: Case report RESULTS: A 40-year-old male patient with history of using cannabis, methamphetamine, synthetic cannabinoid was admitted to our alcohol and substance use disorders research and treatment centre (AMATEM) inpatient unit for detoxification. He has reported that he was injured by a car accident five years ago, had a surgery and was hospitalized for a few months, and started to use substance to relieve pain. According to the medical records, the left frontal and temporoparietal regions were affected. He reported no history of substance abuse before injury, no previous history of psychiatric admission. Personality and behavior changes had been observed after TBI. In the first examination he had depressed mood and loss of interest. Sertraline (gradually titrated up to 150 mg/d) and risperidone (1 mg/d) were started. Also N-acetylcysteine (1,200 mg/d) was added to reduce craving and drug-seeking behaviours for four weeks. CONCLUSIONS: Frontal lobe syndrome and TBI may differ in terms of clinical presentations. Substance use may be a way to cope with mental, cognitive or behavioural changes, psychosocial stressors, anxiety, sleep problems or pain after TBI. DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9567839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95678392022-10-17 Polysubstance Use After Frontal Lobe Syndrome: A Case Report Ulusoy, M. Ergelen, M. Eur Psychiatry Abstract INTRODUCTION: Frontal lobe syndrome (FLS) is a clinical condition characterized by personality and behavioral changes that usually occur after a traumatic brain injury (TBI). The main features of this syndrome are related to the deterioration of basic functions of the frontal lobe. Substance use disorder (SUD) is rare but also serious comorbiditiy seen after TBI. OBJECTIVES: In this case report, we aimed to discuss a case who developed SUD after TBI. METHODS: Case report RESULTS: A 40-year-old male patient with history of using cannabis, methamphetamine, synthetic cannabinoid was admitted to our alcohol and substance use disorders research and treatment centre (AMATEM) inpatient unit for detoxification. He has reported that he was injured by a car accident five years ago, had a surgery and was hospitalized for a few months, and started to use substance to relieve pain. According to the medical records, the left frontal and temporoparietal regions were affected. He reported no history of substance abuse before injury, no previous history of psychiatric admission. Personality and behavior changes had been observed after TBI. In the first examination he had depressed mood and loss of interest. Sertraline (gradually titrated up to 150 mg/d) and risperidone (1 mg/d) were started. Also N-acetylcysteine (1,200 mg/d) was added to reduce craving and drug-seeking behaviours for four weeks. CONCLUSIONS: Frontal lobe syndrome and TBI may differ in terms of clinical presentations. Substance use may be a way to cope with mental, cognitive or behavioural changes, psychosocial stressors, anxiety, sleep problems or pain after TBI. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567839/ http://dx.doi.org/10.1192/j.eurpsy.2022.2142 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Ulusoy, M. Ergelen, M. Polysubstance Use After Frontal Lobe Syndrome: A Case Report |
title | Polysubstance Use After Frontal Lobe Syndrome: A Case Report |
title_full | Polysubstance Use After Frontal Lobe Syndrome: A Case Report |
title_fullStr | Polysubstance Use After Frontal Lobe Syndrome: A Case Report |
title_full_unstemmed | Polysubstance Use After Frontal Lobe Syndrome: A Case Report |
title_short | Polysubstance Use After Frontal Lobe Syndrome: A Case Report |
title_sort | polysubstance use after frontal lobe syndrome: a case report |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567839/ http://dx.doi.org/10.1192/j.eurpsy.2022.2142 |
work_keys_str_mv | AT ulusoym polysubstanceuseafterfrontallobesyndromeacasereport AT ergelenm polysubstanceuseafterfrontallobesyndromeacasereport |